

CURRICULUM VITAE

Richard H. Mattson, M.D.

Dept. of Neurology
Yale Univ. School of Medicine
15 York Street
PO Box 208018
New Haven, CT 06520

Home:
52 Soundview Heights
Branford, CT 06405
Home Phone: 203-483-8193
Cell Phone: 203-376-5710

Phone: 203-785-3865

Fax: 203-785-5694
email: richard.mattson@yale.edu

Birthdate: May 9, 1931

Education: The Taft School, Watertown, Connecticut 1949
Yale University, New Haven, Connecticut, B.S. 1953
Boston University, Boston, Massachusetts, M.D. 1957
University of Minnesota, Minneapolis, M.S. 1962
Yale University, New Haven, Connecticut M.A. (Hon) 1967

Internship: Wilford Hall United States Air Force Hospital 1957 - 1958

Residency: Neurology, Mayo Foundation 1958 - 1962
Neurophysiology, Mayo Foundation 1961 - 1962

Sabbatical: NINDS Epilepsy Branch: with Harvey Kupferberg, PhD. 1988
Basic Mechanisms of Antiepileptic Drugs

Military: Active Duty, Major, U.S. Air Force (USAF) 1957 - 1967
Chief, Neurology Service, Wilford Hall USAF Hospital
Flight Medical Officer
Consultant in Neurology to the USAF Surgeon General
Neurology Advisor to Manned Orbital Lab

Academic Appointments:

Clinical Assistant Professor, Neurology, 1966 - 1967
University of Texas, Medical Branch, Galveston
Assistant Professor, Neurology, Yale University School of Medicine (YMS) 1967 - 1971
Associate Clinical Professor, Neurology, YMS 1971 - 1977
Clinical Professor of Neurology, YMS 1977 - 1983
Professor of Neurology, YMS 1983 - 2003
Professor Emeritus in Neurology 2003-
Senior Research Scientist 2003-
Director Yale Neurology Residency Program 1983- 1996
Director of Medical Studies (Education), Department of Neurology, YMS 1985 - 2002
Director, Clinical Neuroscience Clerkship 1990 - 2002

Richard H. Mattson, M.D.

Chairman , Neuroscience and Psychiatry Module YMS 2	1990 - 2002
Vice Chairman for Academic Affairs, Department of Neurology, YMS	1996 – 1999
Director , Yale/NIH Program Project Grant	1985 -2003
Clinical Curriculum Committee, YMS	1985 -2002
Admissions Committee, YMS	1992 -1999
Secretary, Yale Neurology Alumni Association	1994 -
Co-Director (Interim) Yale Comprehensive Epilepsy Program	2009-2011

Board Certification:

National Board of Medical Examiners	1960
American Board of Psychiatry and Neurology (N)	1964
American Board of Clinical Neurophysiology	1966
American Board of Electromyography and Electrodiagnosis	

Honors or Recognition:

Begg Honor Society, Boston University School of Medicine	1955
HV Jones Medical Science Research Award, Mayo Foundation	1962
Citation- Wilford Hall USAF Hospital	1967
Outstanding Clinical Trial: International League Against Epilepsy (ILAE)	1986
Ambassador Award, ILAE	1989
Best Doctors in the USA	1992-2015
Silver "Cindy" Award for best Educational Video (EFA).	1993
William J. Lennox Award, American Epilepsy Society (AES)	1994
Who's Who in the World (America, Healthcare, Science)	1996-2015
Hans Berger Lecturer	1997
ILAE/IBE Epileptology Prize	1997
American Epilepsy Society (MILLKEN) Clinical Investigator Award	1997
Hans Berger Distinguished Scholar Award	2001
Alpha Omega Alpha Alumni Member, Boston Univ. School of Medicine	2008

Hospital Appointments:

Chief , Neurology Service, Wilford Hall USAF Hospital	1963 - 1967
Consultant in Neurology, Connecticut Mental Health Center	1967 - 1969
Assistant Chief, Neurology Service, Veterans Administration Medical Center (VAMC)	1967 - 1978
Attending in Neurology, Hospital of St. Raphael	1967 - 1983
Chief , Seizure Clinic, Yale-New Haven Hospital	1973 - 1978
Chief , Neurology Service, VAMC, West Haven	1978 - 1993
Attending in Neurology, Yale New Haven Hospital	1967 -
Director , Epilepsy Center, Yale - VAMC	1967– 1978
Chief, Epilepsy Division YMS and YNHH	2009-2011
Chief, EEG Section YMS and YNHH	2009-2011

Director, Epilepsy Fellowship, Yale Comprehensive Epilepsy Center

2009-

Society Memberships:

New Haven County Medical Association
Connecticut Neurological Society
American Medical Association
The American Academy of Neurology (AAN Fellow)
The American Neurological Association (ANA)
The American Clinical Neurophysiology Society (ACNS)(fellow)
The American Epilepsy Society (AES), **Past President**
Southern Clinical Neurological Society, **Past President**
The American Association for Advancement of Science (past)
The Association for Research in Nervous and Mental Diseases (past)

Editorial Boards (past):

Clinical Therapeutics (past)
CNS Drug Reviews (past)
Seizure (past)
Ad Hoc Reviewer: Acta Neurologica Scandinavia, Annals of Neurology, Archives of Neurology, Drugs, Epilepsia, Lancet, JAMA, New England Journal of Medicine, Neurology,

Other Appointments:

CT Epilepsy Foundation PAB	1975-
Chairman , VA Multi-Center Cooperative Study "Efficacy of Antiepileptic Drugs in the Treatment of Specific Seizure Types"	1976-
Co-Chairman J Kiffen Penry Epilepsy Educational Program	1997-
Chairman , International League Against Epilepsy, Commission on Therapeutic Strategies	1997-2001
ILAE Commission on Therapeutic Strategies, member	2001-2005
ILAE Sub-Commission on AED Guidelines	1998-
American Epilepsy Society Awards Committee	2001-2004
Chairman , J Kiffen Penry Award Committee	2001
Advisory Committee member to Abbott, Eisai, Glaxo, Lundbeck, Novartis, Ortho, Pfizer, Shire, Sunovion, Upshaw-Smith and UCB pharmaceutical companies.	1980-
National Advisory Committee, VA Epilepsy Centers of Excellence	2011-

Past Special Appointments (Selected):

Examiner, American Board of Neurology and Psychiatry	1967 -
Examiner, American Board of Qualifications in Clinical Neurophysiology	1967-
Chairman , Program Committee, American Association of Electromyography and Electrodiagnosis	1973
Program Committee, AAN	1974 and 1975
Chairman , VAMC Workshops on Epilepsy	1974 and 1976
Chairman , Special Committee which developed guidelines, "Standards of Clinical Electroencephalographers", ACNS	1975
Vice Chairman , Connecticut Governor's Commission on Epilepsy	1976
Chairman , Research and Development Committee, VAMC	1977 and 1978
Epilepsy Advisory Council, National Institutes of Health	1977 - 1981
Secretary/Treasurer, Connecticut Neurological Society	1977 - 1987
Chairman , Program Committee, Am Epilepsy Soc.	1978
Committee on Flight Standards, Federal Aviation Administration	1979
Pharmacy Committee, VA Cooperative Studies Central Research Program Committee, Epilepsy International	1979 - 1981
Council, American Epilepsy Society	1979 and 1983
Committee on the Classification of Epilepsy, ILAE	1983 - 1987
Chairman , International Symposium on Epilepsy, Hormones and Pregnancy	1976 -1993
Search Committee, YMS Chairman of Surgery	1982 - 1983
President , American Epilepsy Society	1984 - 1985
Dean's Committee, VAMC	1985 - 1986
Cabinet Member, Yale New Haven Hospital	1985 - 1992
Director , Annual Course on Epilepsy AAN	1986 - 1987
Vice President , National Association of Epilepsy Centers	1986 - 1989
Representative for Northeast to Central Office Field Advisory Group in Neurology (VA)``	1987 - 1988
Epilepsy Foundation of America (EFA)	1989 - 1992
Professional Advisory Board	1977 -1996
National Liaison Member for the VA Hospitals	1977 -1996
Advisor to NINDS	1998-2002
Chairman , Symposium on Tolerance to Antiepileptic Drugs, International League Against Epilepsy Paris, France	2005

VISITING PROFESSOR OR LECTURER (USA)

Albany Medical College
Allegheny Medical School
Armed Forces Medical Center, San Antonio
Boston University
Brown University
Cornell Medical School
Dartmouth Medical School
Georgetown Medical School
George Washington University Medical School
Harvard University
Johns Hopkins Medical School

Lahey Clinic
Massachusetts Neurological Association
Mayo Medical School
Medical College of Georgia (Augusta)
Medical College of Pennsylvania
Mount Sinai Medical School, NYC
New Jersey Medical Center, Newark
New Jersey Medical Center, Robert Wood Johnson
New York Medical College
Northwestern Medical School
New York University
Stanford University
SUNY Medical Center, Stonybrook
University of Alabama Medical School, Birmingham
University of Arizona, Tucson
University of California at Los Angeles
University of California at San Diego
University of CT Medical School
University of Massachusetts, Worcester
University of South Carolina Medical School, Columbia
University of South Carolina Medical School, Charleston
University of Southern California
University of Miami Medical School
University of Mississippi Medical School
University of Texas Galveston
University of Texas Houston
University of Texas, Southwestern
University of Washington Medical School
Virginia Commonwealth University

INVITED LECTURER (OVERSEAS)

Bonn University, Germany
Gothenberg Univ, Sweden
Karolinska Institute, Sweden
Kings's College, London UK
University of Paris, France
University of Rome ("la Sapienza")
Messina Medical School, Sicily
Zurich Medical School, Austria
Glasgow University, Scotland
Venice Summer School

ORIGINAL MANUSCRIPTS (not current)

1. Bennett DR, Mattson RH, Ziter FA, Calverley JR, Liske EA, Pratt KL. Sleep deprivation: Neurologic and EEG effects. *Aerospace Med* 35:888-890, 1964.
2. Mattson RH. A good night's sleep. *J Amer Med Assoc* 194:292, 1965.
3. Mattson RH, Pratt KD, Calverley JR. Electroencephalograms of epileptics following sleep deprivation. *Arch Neurol* 13:310-315, 1965.
4. Mattson RH, Peterson EW. Glioblastoma multiform of the optic nerve. *JA A* 196:799-800, 1966.
5. Smith CK, Mattson RH. Seizures in Wilson's Disease. *Neurology* 17:1121-1123, 1967.
6. Mattson RH, Calverley JR. Dextroamphetamine-sulfate induced dyskinesias. *J Amer Med Assoc* 204:400-401, 1968.
7. Mattson RH, Lecocq R. Nerve conduction velocities in fasting patients. *Neurology* 18:335-339, 1968.
8. Pratt KL, Mattson RH, Weikers NJ, Williams R. EEG activation of epileptics following sleep deprivation: A prospective analysis of 114 cases. *EEG Clin Neurophysiol* 24:11-15, 1968.
9. Mattson RH, Weisman GK, Levy LL. Dependence and CNS toxicity associated with the use of propoxyphene hydrochloride. *Trans Amer Neurol Assoc* 94:299-301, 1969.
10. Weikers NJ, Mattson RH. Acute paralytic brachial neuritis. *Neurology* 19:1153-1158, 1969.
11. Gallagher BB, Smith DB, Mattson RH. The relationship of the anticonvulsant properties of primidone to phenobarbital. *Epilepsia* 11:293-301, 1970.
12. Baumel IP, Gallagher BB, Mattson RH. Phenylethylmalonamide (PEMA) - An important metabolite of primidone. *Arch Neurol* 27:34-41, 1972.
13. Gallagher BB, Baumel IP, Mattson RH. Metabolic disposition of primidone and its metabolites in epileptic subjects after single and repeated administration. *Neurology* 22:1186-1192, 1972.

14. Reynolds EH, Gallagher BB, Mattson RH. Relationship between serum and cerebrospinal fluid folate. *Nature* 240:155-157, 1972.
15. Reynolds EH, Mattson RH, Gallagher BB. Relationships between serum and cerebrospinal fluid anticonvulsant drug and folic acid concentrations in epileptic patients. *Neurology* 22:841-844, 1972.
16. Wallace JD, Weintraub MI, Mattson RH, Rosnagle RJ. Status epilepticus as a complication of intrathecal fluorescein. *J Neurosurg* 36:659-660, 1972.
17. Gallagher BB, Baumel IP, Mattson RH, Woodbury SG. Primidone, diphenylhydantoin and phenobarbital. Aspects of acute and chronic toxicity. *Neurology* 23:145-149, 1973.
18. Mattson RH, Gallagher BB, Reynolds EH, Glass DH. Folate therapy in epilepsy: A controlled study. *Arch Neurol* 29:78-81, 1973.
19. Brillman J, Gallagher BB, Mattson RH. Acute primidone intoxication. *Arch Neurol* 30:255-258, 1974.
20. Glass DH, Mattson RH. Paroxysmal EEG activity during fixed ratio and DRL performance of temporal lobe epileptics. *EEG Clin Neurophysio* 37:204-220, 1974.
21. Mattson RH, Williamson PD, Hanahan E. Eterobarb therapy in epilepsy. *Neurology* 26:1014-1017, 1976.
22. Mattson RH, Cramer JA, Williamson PD, Novelly RA. Valproic acid in epilepsy: Clinical and pharmacological effects. *Ann Neurol* 3:20-25, 1978.
23. Cramer JA, Mattson RH. Valproic acid. In vitro plasma protein binding and interaction with phenytoin. *Therap Drug Monit* 1:105-116, 1979.
24. Daly DD, Bennett DR, Crandall PH, Mattson RH, Penry JK, Rasmussen TB. Seizure disorders and disturbances of consciousness - Panel 6. *Arch Neurol* 36:782-783, 1979.
25. Huttenlocher PR, Mattson RH. Isoprinosine in subacute sclerosing panencephalitis. *Neurology* 26:763-771, 1979.
26. Spencer SS, Williamson PD, Spencer DD, Mattson RH. Value of depth electroencephalography in 21 patients with refractory epilepsy. *Trans Amer Neurol Assoc* 104:241-243, 1979.
27. Delaney RC, Rosen AS, Mattson RH, Novelly RA. Memory function in focal epilepsy. A comparison of non-surgical unilateral temporal lobe and frontal lobe samples. *Cortex* 16:103-117, 1980.
28. Fay ML, Mattson RH. Clinical testing during intensive monitoring of ictal events. In: Advances in Epileptology. Tenth Epilepsy International Symposium, eds., JA Wada, JK Penry, Raven Press, New York, 65-68, 1980.
29. Mattson RH. Value of intensive monitoring. In: Advances in Epileptology. Tenth Epilepsy International Symposium, eds., JA Wada, JK Penry, Raven Press, New York, 43-52, 1980.
30. Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. *Ann Neurol* 7:583-584, 1980.
31. Soloway SS, Williamson PD, Spencer DD, Mattson RH. Surgery for epilepsy: Role of depth

- electroencephalography. *Conn Med* 44:70-75, 1980.
32. Williamson PD, Spencer DD, Spencer SS, Mattson RH. Presurgical intensive monitoring using depth electroencephalography in temporal lobe epilepsy. In: Advances in Epileptology. Tenth Epilepsy International Symposium, eds., JA Wada, JK Penry, Raven Press, New York, 73-84, 1980.
 33. Delgado-Escueta AV, Mattson RH, King L, Goldensohn ES, Spiegel H, Madsen J, Crandall P, Dreifuss F, Porter R. Special report. The nature of aggression during epileptic seizures. *N Eng J Med* 305:711-716, 1981.
 34. Spencer SS, Spencer DD, Williamson PD, Mattson RH. Ictal effects of anticonvulsant medication withdrawal in epileptic patients. *Epilepsia* 22:297-307, 1981.
 35. Cramer JA, Mattson RH. A simple method to obtain unbound antiepileptic drugs in blood. *Therap Drug Monit* 4:107-108, 1982.
 36. Mattson GF, Mattson RH, Cramer JA. Interaction between valproic acid and carbamazepine: An in vitro study of protein binding. *Therap Drug Monit* 4:181-184, 1982.
 37. Spencer SS, Spencer DD, Williamson PD, Mattson RH. The localizing value of depth electroencephalography in 32 patients with refractory epilepsy. *Ann Neurol* 12:248-253, 1982.
 38. Cramer JA, Bennett DM, Mattson RH. Free and bound valproic acid separated by two methods of ultrafiltration. *Clin Chem* 29:1441-1442, 1983.
 39. Cramer JA, McCarthy KA, Mattson RH. Free fraction of valproic acid is the same in serum and plasma. *Clin Chem* 29:1449, 1983.
 40. Cramer JA, Smith DB, Mattson RH, Delgado-Escueta AV, Collins JF, the VA Epilepsy Cooperative Study Group. A method of quantification for the evaluation of antiepileptic drug therapy. *Neurology* 33(Suppl 1):28-37, 1983.
 41. Delgado-Escueta AV, Mattson RH, Smith DB, Cramer JA, Collins JF. Principles in designing clinical trials for antiepileptic drugs. *Neurology* 33(Suppl 1):8-14, 1983.
 42. Mattson RH. Closed circuit televised videotape recording and electroencephalography (CCTV/EEG) in convulsive status epilepticus. In: Advances in Neurology. Symposium on Status Epilepticus, eds., AV Delgado-Escueta, CG Wasterlain, DM Treiman, RJ Porter, Raven Press, New York, 37-46, 1983.
 43. Mattson RH, Cramer JA, Delgado-Escueta AV, Smith DB, Collins JF, the VA Epilepsy Cooperative Study Group. A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. *Neurology* 33(Suppl 1):15-27, 1983.
 44. Smith DB, Delgado-Escueta AV, Cramer JA, Mattson RH. Historical perspective on the choice of antiepileptic drugs for the treatment of seizures in adults. *Neurology* 33(Suppl 1):2-7, 1983.
 45. Spencer SS, Spencer DD, Williamson PD, Mattson RH. Sexual automatisms in partial complex seizures. *Neurol* 33:527-533, 1983.
 46. Spilker B, Wilder BJ, Bruni J, Mattson RH, Masland R, Resor S, Wannamaker B, Maddox R, Treiman DM, Geiger E, Peck M, Cloutier G. A multi-center study of the efficacy and safety of cinromide in patients with

- partial seizures. *Curr Therap Res* 34:7-14, 1983.
47. Swick CT, Williamson PD, Mattson RH, Spencer SS, Spencer DD. Depth electroencephalography. *Am J EEG Tech* 23 #1 March, 1983.
 48. Chatot CL, Klein NW, Clapper ML, Resor SR, Singer WD, Russman BS, Holmes GL, Mattson RH, Cramer JA. Human serum teratogenicity studied by rat embryo culture: Epilepsy, anticonvulsant drugs and nutrition. *Epilepsia* 25:205-216, 1984.
 49. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: A preliminary report. *Neurology* 34:1255-1258, 1984.
 50. Mattson RH, Cramer JA, Siconolfi BC, Caldwell BV. Medroxy progesterone therapy for catamenial epilepsy. In: *Advances in Epileptology: 15th Epilepsy International Symposium*, ed., RJ Porter, Raven Press, New York, 279-282, 1984.
 51. Novelly RA, Augustine EA, Mattson RH, Glaser GH, Williamson PD, Spencer DD, Spencer SS. Selective memory improvement and impairment in temporal lobectomy for epilepsy. *Ann Neurol* 15:64-67, 1984.
 52. Sostman HD, Spencer DD, Gore JC, Spencer SS, Holcumb W, Williamson PD, Prichard JW, Camputaro C, Greenspan RH, Mattson RH. Preliminary observations on magnetic resonance imaging in refractory epilepsy. *Magn Reson Imaging* 2:301-306, 1984.
 53. Spencer DD, Spencer SS, Mattson RH, Williamson PD. Intracerebral masses in patients with intractable partial epilepsy. *Neurology* 34:432-436, 1984.
 54. Spencer DD, Spencer SS, Mattson RH, Williamson PD, Novelly RA. Access to the posterior medial temporal lobe structures in the surgical treatment of temporal lobe epilepsy. *Neurosurgery* 15:667-671, 1984.
 55. Spencer SS, Spencer DD, Mattson RH, Williamson PD. More intense focal seizure types after callosal section. The role of inhibition. *Ann Neurol* 16:686-693, 1984.
 56. Goodman RN, Williamson PD, Reeves AC, Spencer SS, Spencer DD, Mattson RH, Roberts DW. Interhemispheric commissurotomy for congenital hemiplegics with intractable epilepsy. *Neurology* 35:1351-1354, 1985.
 57. Mattson RH, Cramer JA. Epilepsy, sex hormones and antiepileptic drugs. *Epilepsia* 26(Suppl 1):S40-S51, 1985.
 58. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. *N Eng J Med* 313:145-151, 1985.
 59. Spencer SS, Spencer DD, Williamson PD, Mattson RH. The effects of corpus callosum section on secondary bilaterally synchronous interictal electroencephalographic discharge. *Neurology* 35:1689-1694, 1985.

60. Spencer SS, Williamson PD, Bridgers SL, Mattson RH, Cicchetti DV, Spencer DD. Reliability and accuracy of localization by scalp ictal EEG. *Neurology* 35:1567-1575, 1985.
61. Williamson PD, Mattson RH, Spencer SS, Spencer DD. Complex partial status epilepticus: A depth electrode study. *Ann Neurol* 18: 647-654, 1985.
62. Williamson PD, Spencer DD, Spencer SS, Novelly RA, Mattson RH. Complex partial seizures of frontal lobe origin. *Ann Neurol* 18:497-504, 1985
63. Williamson PD, Spencer DD, Spencer SS, Novelly RA, Mattson RH. Episodic aphemia and epileptic focus in non-dominant hemisphere: Relieved by section of corpus callosum. *Neurology* 35:1069-1071, 1985.
64. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic concentrations in sole and multi-drug therapy. *Ther Drug Monit* 8:411-415, 1986.
65. Delaney RC, Prevey ML, Mattson RH. Short-term retention with lateralized temporal lobe epilepsy. *Cortex* 22:591-600, 1986.
66. Eskenazi B, Cain WS, Novelly RA, Mattson RH. Odor perception in temporal lobe epilepsy patients with and without temporal lobectomy. *Neuropsychologia* 24:553-562, 1986.
67. Mattson RH. Intensive neurodiagnostic monitoring: Strategy for optimal use. In: Intensive Neurodiagnostic Monitoring, ed., R Gumnit, Raven Press, New York, 281-290, 1986.
68. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Early tolerance to antiepileptic drug side-effects: A controlled trial of 247 patients. In: Tolerance to Beneficial and/or Adverse Effects of Antiepileptic Drugs, eds., HH Frey, et al., Raven Press, New York, 149-156, 1986.
69. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. *J Amer Med Assoc* 256:238-240, 1986.
70. Novelly RA, Schwartz MM, Mattson RH, Cramer JA. Behavioral toxicity associated with antiepileptic drugs: Concepts and methods of assessment. *Epilepsia* 24:331-340, 1986.
71. Smith DB, Craft BR, Collins JF, Mattson RH, Cramer JA, the VA Cooperative Study Group 118. Behavioral characteristics of epilepsy patients compared with normal controls. *Epilepsia* 27:760-768, 1986.
72. Browne TR, Mattson RH, Penry JK, et al. Vigabatrin for refractory complex partial seizures: Multicenter single-blind study with long-term follow up. *Neurology* 37:184-189, 1987.
73. Cramer JA, Collins JF, Mattson RH. Can categorization of patient background problems be used to determine early termination in a clinical trial? *Controlled Clin Trials* 9:47-63, 1987.
74. Homan RW, Miller B, the VA Epilepsy Cooperative Study Group (Mattson RH). Causes of treatment failure with antiepileptic drugs vary over time. *Neurology* 37:1620-1623, 1987.
75. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B, the VA Cooperative Study Group 224. Results of a nationwide Veterans Administration cooperative study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. *Epilepsia* 28:S50-S58, 1987.

76. Spencer SS, Williamson PD, Spencer DD and Mattson RH. Human hippocampal seizure spread studied by depth and subdural recording: The hippocampal commissure. *Epilepsia* 28:479-489, 1987.
77. Mattson RH, Cramer JA. Crossover from polytherapy to valproate monotherapy in primary generalized epilepsy. *Am J Med* 84(Suppl 1A):S23-S28, 1988.
78. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Aspects of compliance in epilepsy: Taking drugs and keeping clinic appointments. In: Compliance in Epilepsy (Epilepsy Research, Suppl 1), eds., I Leppik, D Schmidt, Elsevier, 111-117, 1988.
79. Prevey ML, Delaney RC, Mattson RH. Gist recall in temporal lobe seizure patients. *Cortex* 24:301-312, 1988.
80. Prevey ML, Delaney RC, Mattson RH. Metamemory in temporal lobe epilepsy. Self monitoring of memory functions. *Brain Cogn* 7:298-311, 1988.
81. Sass KJ, Spencer DD, Spencer SS, Novelly RA, Williamson PD, Mattson RH. Corpus callosotomy for epilepsy II: Neurological and neuropsychological outcome. *Neurology* 38:24-28, 1988.
82. Spencer SS, Spencer DD, Williamson PD, Sass KJ, Novelly RA, Mattson RH. Corpus callosotomy for epilepsy I: Seizure effects. *Neurology* 38:19-24, 1988.
83. Bronen R, Cheung G, Charles J, Spencer DD, Spencer SS, Baca S, Williamson PD, Mattson RH. Pathology study of mesial temporal sclerosis: Comparison of scalp, EEG, MR, CT, angiography. *American Society of Neuroradiology*, Orlando, March 19-24, 1989.
84. Browne TR, Mattson RH, Penry JK, et al. A multicenter study of vigabatrin for refractory complex partial seizures in the United States. *Brit J Clin Pharmacol* 27(Suppl 1):955-1005, 1989.
85. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. *J Amer Med Assoc* 261:3273-3277, 1989.
86. Delaney RC, Prevey ML, Mattson RH. Memory scanning and material-specificity with lateralized temporal lobe epilepsy. *J Clin Exp Neuropsychol* 11:48-49, 1989.
87. The Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome (Mattson RH). Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. *Epilepsia* 30(Suppl 4):422-429, 1989.
88. Mattson RH, Cramer JA, McCutchen CB, the VA Epilepsy Cooperative Study Group. Barbiturate related connective tissue disorders. *Arch Intern Med* 149:911-914, 1989.
89. Mattson RH, Cramer JA, Scheyer RD, Hochholzer JM. Disinduction of valproate metabolism: Timing and magnitude of change. *Proc Roy Soc Med Symposium Series* 152:138-142, 1989.
90. Mattson RH, Prevey ML, Cramer JA, Novelly RA, Swick CT. Lifestyle changes in epilepsy patients following treatment with valproate. *Proc Roy Soc Med Symposium Series* 152:275-280, 1989.
91. Mikati MA, Browne TR, Collins JF, the VA Epilepsy Cooperative Study Group (Mattson RH). Time course of carbamazepine autoinduction. *Neurology* 39:592-594, 1989.

92. Prevey ML, Mattson RH, Cramer JA. Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. *Neurology* 39:1640-1641, 1989.
93. Warrenburg S, Levine J, Schwartz GE, Fontana AF, Kerns RD, Delaney R, Mattson RH. Defensive coping and blood pressure reactivity in medical patients. *J Behav Med* 12:407-424, 1989.
93. Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. *Arch Intern Med* 150:1509-1510, 1990.
94. Mattson RH. Selection of drugs for the treatment of epilepsy. *Semin Neurol* 10:406-412, 1990.
95. Mattson RH, Fay ML, Sturman JK, Cramer JA, Wallace JD, Mattson EM. The effect of various patterns of alcohol use on seizures in patients with epilepsy. In: Alcohol and Seizures: Basic mechanisms and clinical concepts, eds., RJ Porter, RH Mattson, JA Cramer, I Diamond, FA Davis, Philadelphia, 233-240, 1990.
96. Nuwer MR, Browne TR, Dodson WE, Dreifuss FE, Engel J, Leppik IE, Mattson RH, Penry J, Treiman DW, Wilder BJ. Generic substitutions for antiepileptic drugs. *Neurology* 40:1647-1651, 1990.
97. Scheyer RD, Cramer JA, Toftness BR, Hochholzer JM, Mattson RH. In vivo determination of valproate binding constants during sole and multi-drug therapy. *Ther Drug Monit* 12:117-123, 1990.
98. Spencer SS, Spencer DD, Williamson PD, Mattson RH. Combined depth and subdural electrode investigation in uncontrolled epilepsy. *Neurology* 40:74-79, 1990.
99. Boon PA, Williamson PD, Fried I, Spencer DD, Novelly RA, Spencer SS, Mattson RH. Intracranial, intraaxial, space-occupying lesions in patients with intractable partial seizures: An anatomoclinical, neuropsychological, and surgical correlation. *Epilepsia* 32:467-476, 1991.
100. Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachen E, McBride RG, Sherry KM. Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: An update. *Neurology* 41:363-364, 1991.
101. Hirsch LJ, Spencer SS, Spencer DD, Williamson PD, Mattson RH. Temporal lobectomy in patients with bitemporal epilepsy defined by depth electroencephalography. *Ann Neurol* 30:347-356, 1991.
102. Hirsch LJ, Spencer SS, Williamson PD, Spencer DD, Mattson RH. Comparison of bitemporal and unitemporal epilepsy defined by depth electroencephalography. *Ann Neurol* 30:340-346, 1991.
103. Mattson RH. Emotional effects on seizure occurrence. In: Neurobehavioral Problems in Epilepsy, eds., D Smith, D Treiman, M Trimble, Raven Press, New York, 55:453-460, 1991.
104. Prevey ML, Delaney RC, De l'Aune W, Mattson RH. A method of assessing the efficacy of memory rehabilitation techniques using a "real world" memory task: Learning a computer language. *J Rehab Res Development* 4:28, 50-63, 1991.
105. Prevey ML, Delaney RC, Mattson RH, Tice DM. Feeling of knowing in temporal lobe epilepsy: Monitoring knowledge inaccessible to conscious recall. *Cortex* 27:81-92, 1991.

106. Spencer SS, Elequera ED, Williamson PD, Spencer DD, Mattson RH. Evolution of seizure characteristics after callosotomy. *J Epilepsy* 4:149-156, 1991.
107. Delaney RC, Prevey ML, Cramer JA, Mattson RH, the VA Epilepsy Cooperative Study Group 264. Test-retest comparability and control subject data for the Rey-Auditory Verbal Learning Test and Rey-Osterrieth/Taylor Complex Figures. *Arch Clin Neuropsychol* 7:523-528, 1992.
108. Johnson EW, de Lanerolle NC, Kim JC, Sundaresan S, Spencer DD, Mattson RH, Zoghbi SS, Baldwin RM, Hoffer PB, Seibyl JP, Innis RB. Central and peripheral benzodiazepine receptors. *Neurology* 42:811-815, 1992.
109. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group 264. A comparison of valproate with carbamazepine for the treatment of partial seizures and secondarily generalized tonic-clonic seizures in adults. *N Eng J Med* 327:765-771, 1992.
110. Sutherling W, et al. (Mattson RH). Assessment: Magnetoencephalography. *Neurology* 42:1-4, 1992.
111. Williamson PD, Boon PA, Thadani VM, Darcey TM, Spencer DD, Spencer SS, Novelly RA, Mattson RH. Parietal lobe epilepsy: Diagnostic considerations and results of surgery. *Ann Neurol* 31:193-201, 1992.
112. Williamson PD, Thadani VM, Darcey TM, Spencer DD, Spencer SS, Mattson RH. Occipital lobe epilepsy: Clinical characteristics, seizure spread patterns, and results of surgery. *Ann Neurol* 31:3-13, 1992.
113. French JA, Williamson PD, Thadani VM, Darcey TM, Mattson RH, Spencer SS, Spencer DD. Characteristics of medial temporal lobe epilepsy: I. Results of history and physical examination. *Ann Neurol* 34:774-780, 1993.
114. Mattson RH, Rebar RW. Contraceptive methods for women with neurologic disorders. *Am J Obstet Gynecol*, 168:2027-2032, 1993.
115. Rothman DL, Petroff OAC, Behar KL, Mattson RH. Localized ¹H NMR measurements of gamma-aminobutyric acid in human brain in vivo. *Proc Natl Acad Sci (Neurobiology)* 90:1-5, 1993.
116. Scheyer RD, Hochholzer JM, Mattson RH. Near-patient rapid assay of phenytoin concentrations. *Epilepsia* 36: 1118-1125, 1993.
117. Spencer SS, Katz A, Ebersole JS, Novotny E, Mattson RH. Ictal EEG changes with corpus callosum section. *Epilepsia* 34:568-573, 1993.
118. Spencer SS, Spencer DD, Sass K, Westerveld M, Katz A, Mattson RH. Anterior, total, and two stage corpus callosum section: Differential and incremental seizure responses. *Epilepsia* 34:561-567, 1993.
119. The U.S. Gabapentin Study Group No.5, Mclean MJ, et al. (Mattson RH). Gabapentin as add on therapy in refractory partial epilepsy. *Neurology* 43:2292-2298, 1993.
120. Williamson PD, French JA, Thadani VM, Kim JH, Novelly RA, Spencer SS, Spencer DD, Mattson RH. Characteristics of medial temporal lobe epilepsy: II. Interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results, and pathology. *Ann Neurol* 34:781-787, 1993.
121. Mattson RH. Current challenges in the treatment of epilepsy. *Neurology* 44(Suppl 5):S4-S9, 1994.

122. Mattson RH, Petroff OAC, Rothman DL, Behar KL. Vigabatrin: Effects on human brain GABA levels by nuclear magnetic resonance spectroscopy. *Epilepsia* 53(Suppl 5):S29-S34, 1994.
123. Messenheimer J, et al. (Mattson RH). Lamotrigine therapy for partial seizures: A multicenter placebo-controlled, double-blind, cross-over trial. *Epilepsia* 35:113-121, 1994.
124. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Effect on brain GABA of standard and high-dose vigabatrin in humans. *Ann Neurol* 36:296, 1994.
125. Saygi S, Spencer SS, Scheyer RD, Katz A, Mattson RH, Spencer DD. Differentiation of temporal lobe ictal behavior associated with hippocampal sclerosis and tumors of temporal lobe. *Epilepsia* 35:737-742, 1994.
126. Scheyer RD, Cramer JA, Mattson RH, the VA Cooperative Study Group 118. A pharmacodynamic approach to the estimate of carbamazepine autoinduction. *J Pharm Sci* 83:491-494, 1994.
127. Scheyer RD, During MJ, Cramer JA, Toftness BR, Hochholzer JM, Mattson RH. Simultaneous HPLC analysis of carbamazepine and carbamazepine epoxide in human brain microdialysate. *J Liquid Chromatogr* 17:1567, 1994.
128. Scheyer RD, During MJ, Hochholzer JM, Spencer DD, Cramer JA, Mattson RH. Phenytoin concentrations in the human brain: An in vivo microdialysis study. *Epilepsy Research* 18:227-232, 1994.
129. Scheyer RD, During MJ, Spencer DD, Cramer JA, Mattson RH. Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. *Neurology* 44:1469-1472, 1994.
130. The U.S. Gabapentin Study Group (Mattson RH). The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. *Epilepsy Research* 18:67-73, 1994.
131. Mattson RH. Antiepileptic drug monitoring: A reappraisal. *Epilepsia* 36(Suppl 5):S22-S29, 1995.
132. Mattson RH. Comparing antiepileptic drugs. *The Lancet* 345:467-468, 1995.
133. Mattson RH. Efficacy and adverse effects of established and new antiepileptic drugs. *Epilepsia* 36(Suppl 2):S13-S26, 1995.
134. Mattson, RH. Update on pharmacotherapy for seizure disorders. *Federal Practitioner (Suppl)*, 1995.
135. Mattson RH, Petroff OAC, Rothman D, Behar K. Vigabatrin: Effect on brain GABA levels measured by nuclear magnetic resonance spectroscopy. *Acta Neurol Scand* 162(Suppl):27-30, 1995.
136. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Initial observations in the effect of vigabatrin on the in vivo 1H spectroscopic measurements of GABA, glutamate, and glutamine in human brain: The effect of vigabatrin. *Epilepsia* 36:457-464, 1995.
137. Scheyer RD, Hochholzer JM, Mattson RH. Near-patient rapid assay of carbamazepine concentrations. *J Epilepsy*, 8:99-103, 1995.
138. Kocsis JD, Mattson RH. GABA levels in the brain: A target for new antiepileptic drugs. *The Neuroscientist* 2(Suppl 6):326-334, 1996.

139. Mattson RH. Parenteral antiepileptic/anticonvulsant drugs. *Neurology* 46(Suppl 1):S8-S13, 1996.
140. Mattson RH. The Role of the Old and the New Antiepileptic Drugs in Special Populations: Mental and Multiple Handicaps. *Epilepsia*, 37 (Suppl 6):s45-s53, 1996
141. Mattson RH, Cramer JA, Collins J, the VA Cooperative Epilepsy Study Group. Prognosis for total control of complex partial and secondary generalized tonic-clonic seizures. *Neurology* 47:68-76, 1996.
142. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. *Ann Neurol* 39:95-99, 1996.
143. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. *Neurology* 47:1567-1571, 1996.
144. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain gamma-aminobutyric acid (GABA) levels and seizure control following initiation of vigabatrin therapy. *Journal of Neurochemistry* 47:1567-1571, 1996.
145. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA levels rise following initiation of vigabatrin therapy, but fail to rise further with increasing dose. *Neurology* 46:1459-1463, 1996.
146. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Low brain GABA is associated with poor seizure control. *Ann Neurol* 40:908-911, 1996.
147. Prevey ML, Delaney RC, Cramer JA, Mattson RH, Collins JF, Cattanach L. The effect of valproate on cognitive functioning: A comparison with carbamazepine. *Archives of Neurology* 53:1008-1016, 1996.
148. Petroff OAC, Mattson RH, Behar KL, Hyder F, Rothman DL. Vigabatrin increases human brain homocarnosine and improves seizure control. *Ann Neurol* 1998; 44: 948-952.
149. Mattson RH, Rothman DL, Behar KL, Petroff OAC. Gabapentin: a GABA active drug. *Epilepsia* 1997; 38 (suppl 3): 65-66.
150. Petroff OAC, Mattson RH, Behar KL, Hyder F, Rothman DL. Vigabatrin increases human brain homocarnosine and improves seizure control. *Ann Neurol* 1998; 44:948-952.
151. Chadwick DL et al (Mattson RH) Report on the Commission on Antiepileptic Drugs. Considerations on Designing Clinical Trials to Evaluate the Place of New Antiepileptic Drugs in the Treatment of Newly Diagnosed and Chronic Patients with Epilepsy. *Epilepsia* 1998; 39: 799-803.
152. Mattson RH. An overview of the new antiepileptic drugs. *The Neurologist*. Sept 1998; 4 (suppl 5): S2-S10.
153. Mattson RH. Medical management of epilepsy in adults. *Neurology* 1998; 51 (suppl 4): S15-S20.
154. Petroff OAC, Hyder F, Mattson, RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. *Neurology* 1999; 52: 473-478.

155. Cramer JA, Fisher R, Ben-Menachem E, French J, Mattson RH. New antiepileptic drugs: Comparison of key clinical trials. *Epilepsia* 1999; 40 (5): 590-600.
156. Petroff OAC, Hyder F, Collins TL, Mattson RH, Rothman DL. Topiramate increases brain GABA, homocarnosine, and Pyrrolidinone in patients with epilepsy. *Neurology* 1999; 52: 473-478.
157. Petroff OAC, Rothman DL, Behar KL, Hyder F, Mattson RH. Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine and GABA in patients with refractory complex partial seizures. *Seizure* 1999; 8: 120-127.
159. Hyder F, Petroff OAC, Mattson RH, Rothman DL. Localized 1H NMR measurements of 2-pyrrolidinone in patients with epilepsy. *Magnetic Resonance Medicine* 1999; 41: 889-896.
160. Petroff OAC, Hyder F, Collins TL, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine in patients with complex partial seizures. *Epilepsia* 1999; 40: 958-964.
161. Verhoeff NPLG, Petroff OAC, Hyder F, Zoghbi SS, Fujita M Rjeevan N, Collins TL, Seibyl J, Mattson RH, Innis R. Effects of vigabatrin on the GABA-ergic system as determined by Iomazenil SPECT and GABA MRS. *Epilepsia* 1999; 40: 1433-1438.
162. Collins TL, Petroff OAC, Mattson RH. A comparison of four new antiepileptic medications. *Seizure* 2000; 9: 291-293.
163. Petroff OAC, Hyder F, Rothman DL, Mattson RH. Functional imaging in the epilepsies proton MRS: GABA & glutamate. *Adv Neurol* 2000; 83: 263-272.
164. Petroff OAC, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine and pyrrolidinone in epilepsy. *Epilepsia*. 2000; 41: 675-680.
165. Hisama FM, Gruen JR, Choi JJ, Husenovic M, Grigorenko EL, Pauls D, Mattson RH, Gelerntner J, Wood FB, Goei VL. Human GABA_B receptor 1 gene: eight novel sequence variants. *Human Mutation* 2001, vol 17:349-350.
166. Petroff OAC, Hyder F, Rothman DL, Mattson RH. Homocarnosine and seizure control in juvenile myoclonic epilepsy and complex parital seizures. *Neurology* 2001; 56: 709-715.
167. Mattson RH. Monotherapy endpoints. *Epilepsy Research* 2001; 45: 109-117.
168. Mattson RH. Comparative trials: equivalence and differences in clinical trials. *Epilepsy Research* 2001; 45: 105-107.
169. Hisama FM, Mattson RH, Lee HH, Felice K, Petroff OA. GABA and the ornithine d-aminotransferase gene in vigabatrin associated visual field defects. *Seizure*.2001;
170. Zaatreh, MM et al. Frontal Lobe Tumoral Epilepsy: Clinical, Neurophysiological Features and Predictors of Surgical Outcome. *Epilpsia* 2002; 43: 723-727.
171. Delgado-Escueta AV, Mattson RH, King L Goldensohn ES, Spiegel H, Madsen J, Crandall P, Dreifuss F, Porter RJ. The nature of aggression during epileptic seizures. *Epilepsy Behav.* 2002; 3: 550-556.

172. Mattson RH Tricyclic Anticonvulsants: Efficacy in Clinical Trials. *Epilepsy and Behavior*. 2002; 3: S9-S13.
173. Privitera MD, Brodie MJ, Mattson RH et al. Topiramate, carbamazepine and valproate monotherapy: a double-blind comparison in the spectrum of newly diagnosed epilepsy. *Acta Neurologica Scand*. 2003; 107: 165-175.
174. Mattson RH Classification of the idiopathic generalized epilepsies. *Epilepsia*. 2003; 44 Suppl 2:
175. Motomedi M, Nguyen DK, Zaatreh M, Singh S, Westerveld M, Thompson J, Mattson RH, Blumenfeld H, Novotny E, Spencer SS. Levetiracetam Efficacy in Refractory Partial-onset Seizures, Especially after Failed Epilepsy Surgery. *Epilepsia*. 2003; 44: 211-214.
176. Yoon, HH, Kwon HL, Mattson RH, Spencer DD, Spencer SS. Long-term seizure outcome in patients initially seizure-free after resective epilepsy surgery. *Neurology*. 2003; 61: 445-450.
177. Fertig E, Lincoln A, Martinuzzi A, Mattson RH, Hisama FM. Novel LG11 mutation in a family with autosomal dominant partial epilepsy with auditory features. *Neurology*. 2003; 60: 1687-90.
178. Mattson RH Overview: idiopathic generalized epilepsies. *Epilepsia*. 2003; 44 Suppl 2: 2-6.
179. Privitera MD, Brodie MJ, Mattson RH et al. Topiramate, carbamazepine and valproate monotherapy: a double-blind comparison in the spectrum of newly diagnosed epilepsy. *Acta Neurol Scand*. 2003; 107: 165-75.
180. Williams J, Bialer M, Johannessen SI, Kramer G, Levy R, Mattson RH, Perucca E, Patsalos PN, Wilson JF. Interlaboratory variability in the quantification of the new generation of antiepileptic drugs based on external quality assessment data. *Epilepsia*. 2003; 44: 40-5.
181. Mattson RH, Gidal B Fractures, Epilepsy and Antiepileptic Drugs. *Epilepsy and Behavior*. 2004; 5 (suppl, e): 36-40.
182. Mattson RH. Cognitive, Affective and Behavioral Adverse Effects in Adults Secondary to Antiepileptic Drug Use. *Reviews in Neurological Diseases*. 2004; 1 (Suppl. 1): S10-17.
183. Arroyo S, Chadwick D, French J, Mattson R, Perucca E. Epilepsies and convulsive Disorders. In *The IUPHAR Compendium of Basic Principles for Pharmacological Research in Humans*. Edited by du Souich P, Erill S, Orme M. Published by IUPHAR Irvine, Ca. 2004; pp165-182.
184. Petroff, OA, Hyder F, Rothman DL, Mattson RH. Brain homocarnosine and seizure control of patients taking gabapentin or topiramate. *Epilepsia* 2006; 47: 349-8
185. Cloyd J, Hauser WA, Towne A, Ramsay R, Mattson R et al. Epidemiological and Medical Aspects of Epilepsy in the Elderly. *Epilepsy Research* 2006; 68 Suppl 1: 39-48.
186. Glauser, et al. ILAE treatment guidelines : evidence-based analysis of treatment efficacy and effectiveness as initial monotherapy for epileptic seizures and epilepsy syndromes.. *Epilepsia* 2006; 47 (7): 1094-1120.

Richard H. Mattson, M.D.

187. Glauser, T., Ben-Menachem, E., Bourgeois, B., Cnaan, A., Guerreiro, C., Kälviäinen, R., Mattson, R., French, J.A., Perucca, E., Tomson, T. (2013). Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes *Epilepsia*, 2013; 54(3), 551-563.
188. Gauthier A C Mattson R H Clobazam: A Safe, Efficacious and Newly Rediscovered Therapeutic for Epilepsy. *CNS Neuroscience & Therapeutics*. 2015; 1-6.
189. Manges L, Szekely A, Cardoza C & Mattson R. A novel KCNQ2 mutation identified in a patient with benign neonatal familial convulsions followed by Rolandic epilepsy. *J. Pediatric Epilepsy*, in press.
190. Sivaraaju S, Nussbaum, I., Cardoza, C, & Mattson R (2015). Substantial and sustained seizure reduction with ketogenic diet in a patient with Ohtahara's syndrome. *Epilepsy and Behavior Case Reports*, 3, 43-45.
191. Manges L, Gauthier A C, Cardoza, C Mattson R H. A Novel SCN1A Mutation Associated with GEFS+ with Benign and Encephalopathic Epilepsy. Poster Presentation at American Epilepsy society, Dec. 2015 and Submitted to *J Pediatric Epilepsy*.
192. Gauthier A C, Quraishi I Mattson R H. Hypothermia associated with Clobazam therapy. Poster Presentation at the AAN, Vancouver, Apr. 2016. *Epilepsy and Behavior*. In Press.
193. Mattson, RH , Gauthier, AC, A Treatment Option for Partial Onset Seizures. (eslicarbazine acetate). *Neurology Reviews*, Suppl. Dec. 2015.

EDITED BOOKS or SUPPLEMENTS

193. Mattson RH. **The design of clinical studies to assess the efficacy and toxicity of antiepileptic drugs.** *Neurology* 1983; 33 (Suppl 1) No 3.
194. Porter RJ, Mattson RH, Ward AA, Dam M., eds. **Advances in Epileptology.** 15th Epilepsy International Symposium. Raven Press, New York, 1984.
195. Porter RJ, Mattson RH, Cramer JA, Diamond I., eds. **Alcohol and Seizures: Basic mechanisms and clinical concepts.** FA Davis, Philadelphia, 1990.
196. Mattson RH. **Managing epilepsy: The role of gabapentin.** *Neurology* 44: Suppl 5, 1994.
197. Levy RH et al. **Antiepileptic Drugs 3rd Edition** Raven Press, New York, 1987.
198. Levy RH, Mattson RH and Meldrum BS **Antiepileptic Drugs 4th Edition** Raven Press New York 1995.

Richard H. Mattson, M.D.

199. Levy RH, Mattson RH, Meldrum BS, Perucca E. eds. **Antiepileptic Drugs** 5th Edition. Lippincott, Williams and Wilkens, Philadelphia, 2002.
200. Mattson, RH **Idiopathic Generalized Epilepsies**. *Epilepsia* 2003; 44 Suppl 2:
201. Majkowski J et al (Mattson) eds **Antiepileptic Drugs: Combination Therapy and Interactions..** Cambridge University Press Cambridge, UK , 2005.

BOOK CHAPTERS and REVIEWS

202. Mattson RH. The benzodiazepines. In: **Antiepileptic Drugs**, eds., DM Woodbury, JK Penry, RP Schmidt, Raven Press, New York, 497-516, 1972.
203. Mattson RH. Valproate and the management of seizures. In: **Current Neurology**, Vol. 2, eds., HR Tyler, D Dawson, Houghton Mifflin Publishing Co., Boston, 229-248, 1979.
204. Mattson RH. Eterobarb: Clinical aspects. In: **Antiepileptic Drugs**, Second Edition, eds., DM Woodbury, JK Penry, CE Pippenger, Raven Press, New York, 813-816, 1982.
205. Mattson RH. Valproate: Interactions with other drugs. In: **Antiepileptic Drugs**, Second Edition, eds., DM Woodbury, JK Penry, CE Pippenger, Raven Press, New York, 579-589, 1982.
206. Mattson RH, Cramer JA. Phenobarbital and toxicity. In: **Antiepileptic Drugs**, Second Edition, eds., DM Woodbury, JK Penry, CE Pippenger, Raven Press, New York, 351-363, 1982.
207. Mattson RH. Phenobarbital, primidone (mysoline) and mephobarbital (mebaral). In: **Epilepsy: Diagnosis and management**, eds., TR Browne, RG Feldman, Little, Brown and Co., Boston, 191-202, 1983.
208. Mattson RH. Seizures associated with alcohol use and alcohol withdrawal. In: **Epilepsy: Diagnosis and management**, eds., TR Browne, RG Feldman, Little, Brown and Co., Boston, 325-332, 1983.
209. Mattson RH, Cramer JA. Valproic acid. In: **Epilepsy: Diagnosis and management**, eds., TR Browne, RG Feldman, Little, Brown and Co., Boston, 225-234, 1983.
210. Mattson RH. Overview of the interrelationship among seizures, hormones and pregnancy. In: **Advances in Epileptology. 15th Epilepsy International Symposium**, eds., RJ Porter, RH Mattson, AA Ward, M Dam, Raven Press, New York, 197-199, 1984.
211. Mattson RH, Cramer JA. Assessment of antiepileptic drug efficacy and toxicity. In: **Rational Approaches to Anticonvulsant Drug Therapy**, eds., SD Shorvon, GB Birdwood, Hans Huber Publishers, Bern, 22-27, 1984.
212. Ebersole JS, Mattson RH, Williamson PD, Spencer SS, Glaser GH. Monitoring at the West Haven VA-Yale University School of Medicine Epilepsy Center. In: **Long-term Monitoring in Epilepsy** (EEG Suppl 37), eds., J Gotman, JR Ives, P Gloor, Elsevier Science Publishers B.V., Amsterdam, 357-369, 1985.
213. Prichard JW, Mattson RH. Barbiturates: An update. In: **Recent Advances in Epilepsy**, Vol. 3, eds., TA Pedley, BS Meldrum, Churchill Livingstone, Edinburgh, 261-277, 1986.
214. Mattson RH. Selection of antiepileptic drug therapy. In: **Antiepileptic Drugs**, Third Edition, eds., RH Levy, FE Dreifuss, RH Mattson, B Meldrum, JK Penry, Raven Press, New York, 103-115, 1989.
215. Mattson RH, Cramer JA. Phenobarbital toxicity. In: **Antiepileptic Drugs**, Third Edition, eds., RH Levy, FE Dreifuss, RH Mattson, B Meldrum, JK Penry, Raven Press, New York, 341-356, 1989.
216. Mattson RH, Cramer JA. Valproate interactions with other antiepileptic drugs. In: **Antiepileptic Drugs**, Third Edition, eds., RH Levy, FE Dreifuss, RH Mattson, B Meldrum, JK Penry, Raven Press, New York,

- 621-632, 1989.
217. Cramer JA, Mattson RH. Fertility and hormonal changes. In: **Comprehensive Epileptology**, eds., M Dam, L Gram, Raven Press, New York, 289-298, 1990.
218. Mattson RH. Alcohol-related seizures. In: **Alcohol and Seizures: Basic mechanisms and clinical concepts**, eds., RJ Porter, RH Mattson, JA Cramer, I Diamond, FA Davis, Philadelphia, 143-147, 1990.
219. Mattson RH, Cramer JA. Primidone. In: **Comprehensive Epileptology**, eds., M Dam, L Gram, Raven Press, New York, 593-601, 1990.
220. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: **Patient Compliance in Medical Practice and Clinical Trials**, eds., JA Cramer, B Spilker, Raven Press, New York, 123-138, 1991.
221. Mattson RH. Drug treatment of partial epilepsy. In: **Frontal Lobe Seizures and Epilepsies**, eds., P Chauvel, et al., Raven Press, New York, 43:643-650, 1992.
222. Mattson RH. Drug treatment of uncontrolled seizures. In: **Surgical Treatment of Epilepsy** (Epilepsy Research, Suppl 5), ed., WH Theodore, Elsevier Science Publishers, Amsterdam, 29-35, 1992.
223. Cramer JA, Mattson RH. Hormones and epilepsy. In: **Treatment of Epilepsy: Principles and practice**, ed., E Wyllie, Lea & Febiger, Philadelphia, 686-691, 1993.
224. Cramer JA, Mattson RH. Quantitative approaches to seizure severity. In: **Quantitative Assessment of Epilepsy Care: Clinometric applications**, eds., H Meinardi, JA Cramer, GA Baker, A Martins da Silva, Pergamon Press, New York, 55-72, 1993.
225. Mattson RH. Electroencephalographic (polygraphic) studies in the diagnosis of non-epileptic seizures. In: **Non-epileptic Seizures**, AJ Rowan, JR Gates, Butterworth-Heinemann, Boston, 85-93, 1993.
226. Mattson RH, Cramer JA. The choice of antiepileptic drugs in focal epilepsy. In: **Treatment of Epilepsy: Principles and practice**, ed., E Wyllie, Lea & Febiger, Philadelphia, 817-823, 1993.
227. Mattson RH, Cramer JA. Quantitative assessment of adverse drug effects. In: **Quantitative Assessment of Epilepsy Care: Clinometric applications**, eds., H Meinardi, JA Cramer, GA Baker, A Martins da Silva, Pergamon Press, New York, 123-135, 1993.
228. Cramer JA, Mattson RH. Compliance with antiepileptic drug therapy. In: **Antiepileptic Drugs**, Fourth Edition, eds., R Levy, RH Mattson, B Meldrum, Raven Press, New York, 149-159, 1995.
229. Cramer JA, Mattson RH. Phenobarbital toxicity. In: **Antiepileptic Drugs**, Fourth Edition, eds., R Levy, RH Mattson, B Meldrum, Raven Press, New York, 409-420, 1995.
230. Mattson RH. Selection of antiepileptic drug therapy. In: **Antiepileptic Drugs**, Fourth Edition, eds., R Levy, RH Mattson, B Meldrum, Raven Press, New York, 123-135, 1995.
231. Scheyer RD, Mattson RH. Valproate: Interactions with other drugs. In: **Antiepileptic Drugs**, Fourth Edition, eds., R Levy, RH Mattson, B Meldrum, Raven Press, New York, 621-631, 1995.
232. Mattson RH, Cramer JA. The choice of antiepileptic drugs in focal epilepsy. In: **The Treatment of Epilepsy**,

Second Edition, ed., E Wyllie, Williams and Wilkins, Baltimore, 771-778, 1996.

233. Mattson RH. Carbamazepine. In: **Epilepsy, a Comprehensive Textbook**. eds., T Pedley, J Engel, Raven Press, New York, 1996.
234. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Low brain GABA and high glutamate correlate with poor seizure control in patients with complex partial epilepsy. In: **The Third International Symposium on Basic Mechanisms of the Epilepsies**. eds., AV Delgado-Escueta, W Wilson, RW Olsen, RJ Porter. 374-378, 1996.
233. Porter R, Mattson, RH. Alcohol and Drug Abuse. In: **Epilepsy, a Comprehensive Textbook**. eds., T Pedley, J Engel, Raven Press, New York, 1997.
235. Petroff OAC, Behar KL, Rothman DL, Mattson RH. Patients with complex partial seizures have increased occipital glutamate and glutamine. In **Proceedings of the International Society of Magnetic Resonance in Medicine, Vol 1**, International Society of Magnetic Resonance in Medicine, Berkeley, California 1997, p34.
236. Mattson RH, Scheyer RD, Petroff OAC, Doring M, Collins TL, Spencer DD. Novel methods for studying new antiepileptic drug pharmacology. In **Advances in Neurology** 1998; 76: 105-112.
237. Mattson RH Antiepileptic Drug Monotherapy in Adults: Selection and Use in New-Onset Epilepsy. In **Antiepileptic Drugs 5th Edition**. Edited by Levy Rh, Mattson RH, Meldrum BS and Perucca E. Lippincott, Williams and Wilkens. Philadelphia, PA. 2002; pp 72-95.
238. Baulac M, Cramer JA, Mattson RH. Phenobarbital and Other Barbiturates. Toxicity. In **Antiepileptic Drugs, 5th Edition**. Edited by Levy RH, Mattson RH, Meldrem BS and Perucca E. Lippincott, Williams and Wilkens, Philadelphia, PA 2002; pp 528-540.
239. Arroyo S, Chadwick D, French J, Mattson R, Perucca E. Epilepsies and convulsive Disorders. In **The IUPHAR Compendium of Basic Principles for Pharmacological Research in Humans**. Edited by du Souich P, Erill S, Orme M. Published by IUPHAR Irvine, Ca. 2004; pp165-182.
240. Mattson RH Combination therapy with antiepileptic drugs: potential advantages and problems. in **Antiepileptic Drugs: Combination Therapy and Interactions**. eds Majkowski J et al (Mattson) . Cambridge University Press Cambridge, UK. Pages 16-25, 2005.
241. Mattson RH Antiepileptic Drug Interactions with Sex Steroid Hormones. In **Antiepileptic Drugs: Combination Therapy and Interactions**. eds Majkowski J et al (Mattson) . Cambridge University Press. Cambridge, UK .pages 341-349, 2005.
242. Fertig, E J, Mattson RH. Carbamazepine. in *Epilepsy. A Comprehensive Textbook* 2nd Edition. Edited by Engel J and Pedley T. Wolters Kluwer. Philadelphia, PA 2008; 1543-1557.
243. Mattson RH Selection of Antiepileptic Drug Therapy. Wheless and Wilmore.
244. Detyniecki K, Farooque P, Mattson R. *Epilepsy Treatment Strategies*. Encyclopedia of Neurological Sciences, 2nd Edition, eds. MJ Aminoff and RB Daroff, Academic Press, New York, NY
244. Mattson R, Detyniecki K, Farooque P., *Epilepsy, Drug Treatment Principles*. Encyclopedia of Neurological Sciences, 2nd Edition, eds. MJ Aminoff and RB Daroff, Academic Press, New York,

245. Farooque P, Detyniecki K, Mattson R. *Epilepsy, Antiepileptic Drug Profiles*. Encyclopedia of Neurological Sciences, 2nd Edition, eds. MJ Aminoff and RB Daroff, Academic Press, New York, NY

SELECTED ABSTRACTS

(Not Published Elsewhere)

1. Mattson RH, Bickford R. Firing patterns of bilateral strychnine spikes in the cortex of the cat. EEG Clin Neurophysiol 13:144-145, 1961.
2. Mattson RH, Heninger GR, Gallagher BB, Glaser GH. Psychophysiologic precipitants of seizures in epileptics. Neurology 20:407, 1970.
3. Glass DH, Mattson RH. Psychopathology and emotional precipitation of seizures in temporal lobe and nontemporal lobe epileptics. Proceedings of the 81st Annual Convention of the American Psychological Association, 425-426, 1973.
4. Glass DH, Mattson RH. Paroxysmal EEG activity during fixed-ratio and DRL performance of temporal lobe epileptics. EEG Clin Neurophysiol 37:204, 1974.
5. Mattson RH. Subacute sclerosing panencephalitis recovery associated with isoprinosine therapy: Report of a case. Neurology 24:383, 1974.
6. Mattson RH, Lerner E, Dix G. Precipitating and inhibiting factors in epilepsy: A statistical study. Epilepsia 15:271-272, 1974.
7. Eisler J, Mattson RH. Compliance in anticonvulsant drug therapy. Epilepsia 15:203, 1975.
8. Cramer JA, Mattson RH, Brillman J. Folinic acid therapy in epilepsy. Fed Prac 35:582, 1976.
9. Williamson PD, Allison TJ, Goff WR, Mattson RH. Evoked potential abnormalities in epilepsy: The e-wave. EEG Clin Neurophysiol 42:729-730, 1977.
10. Kuhlman WN, Mattson RH. Electroencephalographic feedback training in the treatment of seizures. Mechanism and maintenance of effect. Biofeedback Self-Regul 4:267, 1979.
11. Cramer JA, Mattson RH. Central case validation. Controlled Clin Trials 1:168, 1980.
12. Cramer JA, Collins JF, Mattson RH, the VA Epilepsy Cooperative Study Group. Which patient will be lost in follow-up? Controlled Clin Trials 2:78, 1981.
13. Cramer JA, Mattson RH. Cinromide pharmacokinetics and interactions. Epilepsia 22:235, 1981.
14. Mattson RH, Kamer JM, Cramer JA, Caldwell BV. Seizure frequency and the menstrual cycle: A clinical study. Epilepsia 22:242, 1981.

15. Mattson RH, the VA Cooperative Study Group. Agreement among EEG readers. *EEG Clin Neurophysiol* 53:300, 1982.
16. Cramer JA, Collins JF, Mattson RH, the VA Epilepsy Cooperative Study Group. What happens to study dropouts? *Controlled Clin Trials* 5:307, 1984.
17. Cramer JA, Mattson RH, Bennett DM. Utilization of free valproic acid determinations. *Clin Pharmacokinet* 9:94-95, 1984.
18. Cramer JA, Mattson RH, Collins JF, Browne TF, the VA Epilepsy Cooperative Study Group. Correlation between phenytoin and carbamazepine free fraction and serum albumin. *Epilepsia* 25:674-675, 1984.
19. Mattson RH, Cramer JA, Toftness BR, Mebust K. Testosterone and antiepileptic drugs. *Epilepsia* 26:538, 1985.
20. Cramer JA, Mattson RH, Wannamaker B, et al. Reliability of immunochromatographic assay for phenobarbital and phenytoin. *Epilepsia* 27:621-622, 1986.
21. Curley A, Delaney RC, Mattson RH. Behavior problems in children with seizures and their relation to parental influences. *Epilepsia* 27:615, 1986.
22. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Connective tissue changes, hypersensitivity rash and blood laboratory test changes associated with antiepileptic drug therapy. *Ann Neurol* 20:119-120, 1986.
23. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Etiology of partial epilepsy in 622 adults. *Epilepsia* 27:618, 1986.
24. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Side effects of carbamazepine, phenobarbital, phenytoin and primidone. *Neurology* 36:325, 1986.
25. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Success with alternate antiepileptic drug selection. *Epilepsia* 27:645, 1986.
26. Mattson RH, Cramer JA, Toftness BR, Mattson GF. Postictal changes in prolactin and luteinizing hormone. *Neurology* 36:444, 1986 (letter).
27. Cramer JA, Collins JF, Mattson RH, the VA Epilepsy Cooperative Study Group. Reasons for non-drug related loss to a multicenter epilepsy study. *Controlled Clin Trials* 8:306, 1987.
28. Mattson RH, Cramer JA, Siconolfi BC, Toftness BR, Swick CS. Successful valproate monotherapy for generalized tonic clonic seizures. *Epilepsia* 28:627, 1987.
29. Mattson RH, Toftness BR, Cramer JA. Postictal pituitary hormonal changes. *Neurology* 37(Suppl 1):100-101, 1987.
30. Cramer JA, Prevey ML, Ouellette V, Mattson RH. Can non-compliance be predicted? *Epilepsia* 29(Suppl 5):705, 1988.
31. Delaney RC, Prevey ML, Mattson RH, Cramer JA. Test-retest comparability and control subject data for the

- PASAT, Rey-AVLT, and Rey-Osterrieth/Taylor Figures. *J Clin Exp Neuropsychol* 10(Suppl 1):44, 1988.
32. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Time of next seizure after starting an antiepileptic drug. *Epilepsia* 29(Suppl 5):704, 1988.
 33. Mattson RH, Cramer JA, Toftness B. Prolactin changes following temporal and extra temporal seizures of varying severity. *Epilepsia* 29(Suppl 5):704, 1988.
 34. Prevey ML, Delaney RC, Mattson RH, Cramer JA. Cognitive functioning in seizure patients prior to treatment with antiepileptic drugs. *Epilepsia* 29(Suppl 5):692, 1988.
 35. Ramsay RE, Wilder BJ, Mattson RH, et al. Conversion of polytherapy to valproate monotherapy in patients with tonic clonic seizures. *Epilepsia* 29(Suppl 5):699, 1988.
 36. Schwartz SS, Spencer DD, Novelly, RA, Spencer SS, Sass KJ, Williamson PD, Mattson RH. Preservation of verbal and pictorial memory after anteromedial temporal lobectomy and radical hippocampectomy for temporal lobe epilepsy. *Epilepsia* 29(Suppl 5):677, 1988.
 37. Delaney RC, Prevey ML, Mattson RH. Memory scanning and material-specificity with lateralized temporal lobe epilepsy. *J Clin Exp Neuropsychol* 11(Suppl 1):48-49, 1989.
 38. Mattson RH, Cramer JA, Collins JF, the VA Epilepsy Cooperative Study Group. Analysis of seizure recurrence by etiology. *Neurology* 39(Suppl 1):148, 1989.
 39. Scheyer RD, Cramer JA, Toftness B, Mattson RH. Valproate related tremor. *Epilepsia* 30:639, 1989.
 40. Schumacher GE, Barr JT, Browne TR, the VA Epilepsy Cooperative Study Group (Mattson RH). Using decision analysis to study the usefulness of the serum phenytoin concentration (SPC). *Clin Pharmacol Ther* 45:152, 1989.
 41. Cramer JA, Scheyer RD, Hochholzer JM, Mattson RH, the VA Cooperative Study Group. Carbamazepine assay cross-reactivity. *Neurology* 40(Suppl 1):138, 1990.
 42. Delaney RC, Prevey ML, Mattson RH. Long term recall following learning to criterion in focal temporal lobe epilepsy. *J Clin Exp Neuropsychol* 12(Suppl 1):87, 1990.
 43. Mattson RH, Cramer JA, the VA Epilepsy Cooperative Study Group. Seizure remission after active epilepsy. *Epilepsia* 31:648, 1990.
 44. Prevey ML, Cramer JA, Delaney RC, Mattson RH. Behavioral toxicity battery for antiepileptic drug trials. *Epilepsia* 31(Suppl 5):656, 1990.
 45. Prevey ML, Delaney RC, Tice DM, Mattson RH. Map learning in temporal lobe seizure patients. *J Clin Exp Neuropsychol* 12(Suppl 1):87, 1990.
 46. Scheyer RD, Cramer JA, Mattson RH, the VA Epilepsy Cooperative Study Group 118. Outpatient bayesian non-steady state phenytoin predictions. *Epilepsia* 31:599, 1990.
 47. Spencer SS, Guimaraes P, Katz A, Spencer DD, Mattson RH. Morphological characteristics of seizure onset from intracranial recording. *Epilepsia* 31:663, 1990.

48. Cramer JA, Mattson RH, Scheyer RD. Diagnosis of seizure precipitants using medication monitors. *Neurology* 41(Suppl):366, 1991.
49. Cramer JA, Scheyer RD, Hochholzer JM, Mattson RH, the VA Epilepsy Cooperative Study Group 264. Carbamazepine concentrations and adverse effects. *Epilepsia* 32:14, 1991.
50. Delaney RC, Prevey ML, Tice DM, Mattson RH. A further investigation of the short term memory deficit in lateralized seizure patients: Release from proactive interference. *J Clin Exp Neuropsychol* 13(Suppl 1):42, 1991.
51. Prevey ML, Delaney RC, Cattanach L, Mattson RH. Prediction of memory in temporal and extratemporal seizure patients. *J Clin Exp Neuropsychol* 13(Suppl 1):41, 1991.
52. Cramer JA, Mattson RH, the VA Epilepsy Cooperative Study Group 264. Laboratory test abnormalities during long-term use of carbamazepine and valproate. *Neurology* 42(Suppl 3):331, 1992.
53. Kocsis JD, Mattson RH, Oyelese AA. Modulation of CA1 hippocampal neuronal excitability by inhibition of GABA uptake with nipecotic acid. Society for Neuroscience Abstract, 1992.
54. Mattson RH, Cramer JA, the VA Epilepsy Cooperative Study Group. Seizure remission in adults with epilepsy. *Neurology* 42(Suppl 3):243, 1992.
55. Prevey ML, Delaney RC, Cramer JA, Mattson RH, Collins JF, Cattanach L, the VA Cooperative Study Group 264. Valproate versus carbamazepine: Comparison of effects on cognitive functioning. *Epilepsia* 33(Suppl 3):110, 1992.
56. Cramer JA, Mattson RH, the VA Epilepsy Cooperative Studies 118 and 264 Groups. Control of complex partial and tonic-clonic seizures for one year after starting treatment. *Epilepsia* 34(Suppl 6):50, 1993.
57. Cramer JA, Mattson RH, the VA Epilepsy Cooperative Studies 118 and 264 Groups. Same prognosis for seizure control for patients grouped by pure or predominant seizure type. *Epilepsia* 34(Suppl 6):50, 1993.
58. During M, Mattson RH, Scheyer RD, Rask C, Pierce M, McKelvy J, Thomas V. The effect of tiagabine HCl on extracellular GABA levels in the human hippocampus. *Epilepsia*(Suppl 3):83, 1993.
59. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Estimates of the rate of GABA synthesis in patients with epilepsy. In: *Proceedings of the International Society of Magnetic Resonance in Medicine Vol 2*, Society of Magnetic Resonance, Berkley, California 1996, p962.
60. Petroff, OAC, RothmanDL, Behar KL, Mattson RH. Low brain GABA is associated with poor seizure control in patients with complex partial epilepsy. In: *Proceedings of the International Society of Magnetic resonance in Medicine Vol 1*, Society of Magnetic Resonance, Berkley, California 1996, p131.
61. Petroff OAC, Rothman DL, Behar KL, Collins TL Mattson RH. The acute effects of vigabatrin on brain GABA concentration in patients with intractable epilepsy. *Neurology* 46(Suppl): A227, 1996.
62. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human brain GABA is the same on standard and high dose vigabatrin. *Journal of Neurochemistry* 66(Suppl 1):S82, 1996.

63. Mattson RH, Petroff OAC, Rothman DL, Behar KL, Collins TL. Oral vigabatrin raises human brain GABA within two hours. *Epilepsia* 1996; 37 (suppl 5): 203.
64. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Low Brain GABA is associated with frequent seizures. *Epilepsia* 1996; 37 (suppl 5): 203.
65. Scheyer RD, Assaf BA, Spencer SS, Mattson RH. Gabapentin Related Myoclonus. *Epilepsia* 1996; 37 (suppl 5): 203.
66. Prevey ML, Delaney RC, Mattson RH, Cramer JA, Cattanach L. Behavioral toxicity battery for antiepileptic drug trials: Normative data for subjects 20-80 years of age. *Epilepsia*, 37(Suppl 5):173, 1996.
67. Rothman DL, Behar KL, Mattson RH, Prichard JW, Novotny EJ, Petroff OAC. Homocarnosine levels are elevated in epileptic patients taking vigabatrin: a novel measure of cortical pH. In: *Proceedings of the International Society of Magnetic Resonance Medicine*. Vol. 1, Society of Magnetic Resonance, Berkeley, California 1996, p130.
68. Prevey ML, Cattanach L, Delaney RC, Mattson RH. Behavioral toxicity battery: Comparison of performance by normal, young, middle aged and elderly adults. *Journal of Neuropsychiatry and Clinical Neurosciences* 9(Suppl 1): 166, 1997.
69. Petroff OAC, Rothman DL, Mattson RH. GAMA and homocarnosine measurements and seizure control: The clinical pharmacology of gabapentin. 1997
70. Prevey ML, Mattson RH, Delaney RC, Kim JH, Spencer SS, SpencerDD. Memory scanning in temporal lobe epilepsy: Relationship to hippocampal cell density. *Journal of the International Neuropsychological Society*, 3(Suppl 1):9, 1997.
71. Petroff OAC, Rothman DL, Behar KL, Mattson RH. Human occipital lobe homocarnosine increased after starting vigabatrin. *Annals of Neurology* 1997; 42: 473.
72. Petroff OAC, Behar KL, Rothman DL, Mattson RH. Vigabatrin increased human brain GABA and improved seizure control. *Epilepsia* 1997;38 (suppl 3): 171.
73. Petroff OAC, Mattson RH, Behar KL, Hyder F, Rothman DL. Vigabatrin increases human brain homocarnosine and improves seizure control. *Epilepsia* 1997; 38 (suppl 8): 103-104.
74. Petroff OAC, Hyder F, Rothman DL, Collins TL, Mattson RH. Gabapentin increases human brain GABA within one hour. *Epilepsia* 1998;39 (suppl 6): 71.
75. Collins TL, Petroff OAC, Mattson RH. Comparison of new antiepileptic drug therapy. *Epilepsia* 1998;39 (suppl 6):59-60.
76. Petroff OAC, Hyder F, Collins TL, Mattson RH, Rothman DL. Acute effects of vigabatrin on brain GABA and homocarnosine. *Ann Neurol* 1998;44:498.
77. Petroff OAC, Hyder F, Behar KL, Mattson RH, Rothman DL. Increased homocarnosine is associated with improved seizure control. In proceedings of the International Society of Magnetic Resonance in Medicine, Vol 1, International Society of Magnetic Resonance in Medicine, Berkeley, California 1998, p287.

Richard H. Mattson, M.D.

78. Williamson PD, Thadani VM, French JA, Darcey TM, Mattson RH, Spencer SS, Spencer DD. Medial temporal lobe epilepsy: Video tape analysis of objective clinical seizure characteristics. *Epilepsia* 1999; 39(11): 1182
79. Gautam RM, Walid AS, Mattson RH, Kocsis JD. Gabapentin and vigabatrin enhance promoted GABA release in rat hippocampus in vivo. *Epilepsia*, vol. 40, Suppl. 7, 1999.
80. Petroff, OAC, Hyder F, Collins TL, Rothman DL, Mattson RH. Vigabatrin increases brain GABA within one hour. *Epilepsia*, Vol. 40, Suppl. 7, 1999.
81. Petroff OAC, Hyder F, Rothman, Collins TL, Mattson RH, Rothman DL. Measuring the minimum rate of GABA synthesis in patients with complex partial seizures. *Proc Intl Reson Med* 1999; 7: 463.
82. De Graf RA, Petersen K, Mason GF, Shen J, Behar KL, Shulman GI, Mattson RH, Rothman DL, Petroff OAC. GABA synthesis and cycling in human brain as studied by ¹H and ¹³C NMR spectroscopy. *Proc Intl Soc Mag Reson Med* 2000; 8: 13.

*(stopped recording abstract references at this time)

(references incomplete)

Richard H. Mattson, M.D.